Hologic Recalls BioZorb Implantable Markers, FDA Says

MT Newswires Live07-01

Hologic (HOLX) is recalling its BioZorb and BioZorb LP implantable markers due to complications and adverse events reported with implanted devices, the US Food and Drug Administration said Tuesday.

The FDA said it has identified this recall as the most serious type, adding that continued use of the devices may lead to serious injury or death.

There have been 252 reported injuries, the regulator said, adding that there have been no reports of death.

The firm sent an urgent medical device recall letter on Oct. 24, 2024, with recommended actions, and later issued a follow-up notification on April 6, 2026, providing updated guidance, it said.

Hologic didn't immediately reply to MT Newswires' request for comment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment